Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 10/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 8/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3926130 | 0.85 | CXCR2 (0.64) | CXCR2 | |
| SCHEMBL3934345 | 0.85 | CXCR2 (0.64) | CXCR2 | |
| SCHEMBL3933702 | 0.85 | CXCR2 (0.64) | CXCR2 | |
| SCHEMBL4534699 | 0.85 | CXCR2 (0.59) | CXCR2EGLN1 | |
| SCHEMBL3926196 | 0.77 | CXCR2 (0.46) | CXCR2 | |
| SCHEMBL3927805 | 0.76 | CXCR2 (0.62) | CXCR2ATM | |
| SCHEMBL3936460 | 0.76 | CXCR2 (0.62) | CXCR2ATM | |
| SCHEMBL3926665 | 0.74 | CXCR2 (0.46) | CXCR2 | |
| SCHEMBL3934439 | 0.72 | CXCR2 (0.63) | CXCR2HDAC6 | |
| SCHEMBL3922428 | 0.72 | CXCR2 (0.71) | CXCR2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-8501981-B2 | CXCR2 inhibitors | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
| US-20090227625-A1 | CXCR2 INHIBITORS | SANOFI-AVENTIS (FR) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227625-A1 | CXCR2 INHIBITORS | CXCR2, CXCR1, CXCR4 | CXCR2 1/4885EGLN1 1982/4885ATM 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.